91九色视频

header-logo
Ophthalmology_Hero Image 2
headshot

Thomas B. Connor, MD

Professor

view physician profile

Locations

  • Froedtert Hospital
  • Westbrook Health Center
  • Eye Institute - Froedtert Hospital

Specialties

  • Ophthalmology

Languages

  • English

Eye Institute

Westbrook Health Center

Education

  • MD - Doctor of Medicine

Publications

  • (Writing Committee for the DRCR Retina Network, Ehlers JP, Josic K, Yordi S, Martin A, Srivastava SK, Sun JK.) Ophthalmol Retina. 2025 Mar;9(3):243-252 PMID: 39216727 PMCID: PMC11868455 SCOPUS ID: 2-s2.0-85205692352 09/01/2024

  • (Kolli A, Wong J, Duret S, Stewart JM, Connor TB, Roorda A, Carroll J, Duncan JL.) American Journal of Ophthalmology Case Reports. June 2025;38 SCOPUS ID: 2-s2.0-85218881616 06/01/2025

  • (Hogg HDJ, Brittain K, Talks J, Keane PA, Technology Enhanced Macular Services Study Reference Group, Maniatopoulos G.) Implement Sci Commun. 2024 Nov 26;5(1):131 PMID: 39593115 PMCID: PMC11600873 11/27/2024

  • (Sepah YJ, Do DV, Mesquida M, Day BM, Blotner S, Afridi R, Halim MS, Hong K, Wakshull E, Fauser S, Stoilov I, Dong Nguyen Q, HARBOR, READ-3 Investigators.) Eye (Lond). 2024 Jun;38(9):1755-1761 PMID: 38622330 PMCID: PMC11156666 SCOPUS ID: 2-s2.0-85195531215 04/16/2024

  • (Yu CT, Kandoi S, Periasamy R, Reddy LVK, Follett HM, Summerfelt P, Martinez C, Guillaume C, Bowie O, Connor TB, Lipinski DM, Allen KP, Merriman DK, Carroll J, Lamba DA.) Stem Cell Reports. 2024 Mar 12;19(3):331-342 PMID: 38335965 PMCID: PMC10937153 SCOPUS ID: 2-s2.0-85186065745 02/10/2024

  • (Mahaling B, Low SWY, Ch S, Addi UR, Ahmad B, Connor TB, Mohan RR, Biswas S, Chaurasia SS.) Pharmaceutics. 2023 Jul 22;15(7) PMID: 37514191 PMCID: PMC10383092 SCOPUS ID: 2-s2.0-85166338712 07/29/2023

  • (Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, SCORE2 Investigator Group.) Am J Ophthalmol. 2022 Aug;240:330-341 PMID: 35461831 PMCID: PMC11064059 04/25/2022

  • (Chew EY, Clemons TE, Agrón E, Domalpally A, Keenan TDL, Vitale S, Weber C, Smith DC, Christen W, AREDS2 Research Group.) JAMA Ophthalmol. 2022 Jul 01;140(7):692-698 PMID: 35653117 PMCID: PMC9164119 06/03/2022

  • (Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, SCORE2 Study Investigator Group.) JAMA Ophthalmol. 2022 May 01;140(5):458-464 PMID: 35323843 PMCID: PMC8949717 03/25/2022

  • (Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, SCORE2 Investigator Group.) Graefes Arch Clin Exp Ophthalmol. 2022 May;260(5):1491-1500 PMID: 34842984 PMCID: PMC10887424 11/30/2021

  • (Langlo CS, Trotter A, Reddi HV, Schilter KF, Tyler RC, Udani R, Neitz M, Carroll J, Connor TB.) American Journal of Ophthalmology Case Reports. March 2022;25 SCOPUS ID: 2-s2.0-85121217327 03/01/2022

  • (Mahaling B, Low SWY, Beck M, Kumar D, Ahmed S, Connor TB, Ahmad B, Chaurasia SS.) International Journal of Molecular Sciences. March-1 2022;23(5) SCOPUS ID: 2-s2.0-85125395177 03/01/2022

Publications of from the

© 2025 91九色视频.  All rights reserved.  | Terms and Privacy | Web Accessibility Statement

Non-Discrimination Statement
The 91九色视频 (91九色视频) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, or military status. Employees, students, applicants or other members of the 91九色视频 community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic. 91九色视频’s policy as well as federal and state laws and regulations prohibit unlawful discrimination and harassment.

Notice of Compliance with Laws and Commitment to Civil Rights
The 91九色视频 is committed to full compliance with all applicable federal, state, and local laws and regulations in the pursuit of our missions. Consistent with recent federal guidance, we affirm our commitment to individual merit, fairness, and equal treatment in all aspects of academic and institutional decision-making. As part of this commitment, we are actively reviewing our policies and materials to ensure they align with federal nondiscrimination obligations.